Creating a new gene therapy to reduce seizures in epilepsy patients
Official title: Development and validation of a viral vector for targeted inhibition of DG granule cells
Funded at Emory University · NIH-10877119 · Data updated 2026-11-12
This study is testing a new gene therapy that could help people with drug-resistant epilepsy by targeting certain brain cells to reduce seizures, and it will first be tried out in mice before looking at how it might work for humans.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $195,625 |
| NIH project number | 5R21NS132071-02 |
| Project ID | NIH-10877119 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 21 years old who suffer from drug-resistant epilepsy.
✕Less likely to help
Patients with epilepsy that is well-controlled by existing medications may not benefit from this research.
What this research studies
This research focuses on developing a novel gene therapy aimed at treating drug-resistant epilepsy by targeting specific brain cells known as dentate gyrus granule cells. The approach involves using a viral vector to deliver a gene that can inhibit these cells, potentially reducing the frequency of seizures. The researchers will first test the effectiveness of this gene therapy in a mouse model before considering its application in humans. By understanding how seizures are initiated and propagated, this research aims to provide new treatment options for patients who do not respond to existing medications.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment for patients with drug-resistant epilepsy, significantly improving their quality of life.
How similar studies have gone: While gene therapy for epilepsy is a relatively novel approach, preliminary studies have shown promise in targeting specific brain cells to manage seizures.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Gutekunst, Claire-Anne N — Emory University
- Study coordinator: Gutekunst, Claire-Anne N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.